We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Syncona Limited | LSE:SYNC | London | Ordinary Share | GG00B8P59C08 | ORD NPV |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 1.40 | 1.10% | 128.40 | 127.40 | 128.80 | 128.20 | 125.60 | 125.80 | 791,286 | 16:35:14 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Trust,ex Ed,religious,charty | -39.79M | -56.02M | -0.0840 | -15.17 | 849.42M |
From Apr 2019 to Apr 2024
TIDMSYNC
RNS Number : 5773Z
Syncona Limited
03 September 2018
Syncona Limited
Change of Administrator and Depositary
3 September 2018
Syncona Limited announces that with effect from 1 September 2018:
-- Citco Fund Services (Guernsey) Limited has been appointed as Administrator and Company Secretary of the Company, in place of Northern Trust International Fund Administration Services (Guernsey) Limited; and
-- Citco Custody (UK) Limited has been appointed as Depositary and Custodian of the Company, in place of Northern Trust (Guernsey) Limited.
The Company's registered office address is also changed with effect from 1 September 2018 to:
Arnold House
St Julian's Avenue
St. Peter Port
Guernsey GY1 3RD
Channel Islands
[ENDS]
Enquiries
Syncona Ltd
Annabel Clay
Tel: +44 (0) 20 7611 2031
Copies of this press release and other corporate information can be found on the company website at: www.synconaltd.com
About Syncona:
Syncona is a leading FTSE250 healthcare company focused on investing in and building global leaders in life science. Our vision is to deliver transformational treatments to patients in truly innovative areas of healthcare while generating superior returns for shareholders.
We seek to partner with the best, brightest and most ambitious minds in science to build globally competitive businesses.
We take a long-term view, underpinned by a deep pool of capital, and are established leaders in gene and cell therapy. We focus on delivering dramatic efficacy for patients in areas of high unmet need.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
COSLLFLIAAIVIIT
(END) Dow Jones Newswires
September 03, 2018 06:22 ET (10:22 GMT)
1 Year Syncona Chart |
1 Month Syncona Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
